Understand the source comparison
Cartalax Per Day Daily Dose: Research Comparison
10mcg daily (evening) Subcutaneous 20 days on / 10 days off Gastric mucin production +180%, TFF1 expression +210% (rodent model, Advances in Gerontology) Standard effective protocol. Aligns with circadian transcription patterns and avoids pathway downregulatio
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 10mcg daily (evening)
- Subcutaneous
- 20 days on / 10 days off
- Gastric mucin production +180%, TFF1 expression +210% (rodent model, Advances in Gerontology)
- Standard effective protocol. Aligns with circadian transcription patterns and avoids pathway downregulation
- 20mcg daily (evening)
- 30 days on / 10 days off
- Stress-induced ulcer area reduction by 64% vs control (Russian Journal of Bioorganic Chemistry)
- Upper range of effective dosing. No additional benefit observed above 15mcg in most models
- 10mcg twice daily (morning + evening)
- 30 days continuous
- Minimal transcriptional changes, <20% improvement in mucin markers
- Fails to account for circadian chromatin accessibility. Morning dose largely inactive
- 40mcg daily (evening)
- No significant improvement over 20mcg dose in age-related gastric atrophy study
- Exceeds threshold mechanism. Bioregulators don't follow linear dose-response curves
- 15mcg daily (sublingual, evening)
- Sublingual
- Comparable bioavailability to subcutaneous when held sublingually for 2+ minutes
- Viable alternative for researchers preferring non-injection routes. Requires disciplined administration technique